Can weight gain be prevented in women with breast cancer? A systematic review of intervention studies

Thomson, Zoe O.; Reeves, Marina M.

doi:10.1016/j.orcp.2016.10.274

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even patients who do not gain weight during treatment may exhibit deleterious body composition changes (ie, concomitant losses of fat‐free mass [FFM] and gains in fat mass [FM] with no net change in body mass) that contribute to adverse disease‐specific and overall health outcomes 10 . Weight management through exercise and nutrition programs has become an important component of breast cancer rehabilitation, 6,11 and practical evaluation of changes in body composition features as they relate to the disease trajectory, or as a measure of efficacy of nutrition and exercise programs, is needed in this patient population.…”

Section: Introductionmentioning

confidence: 99%

Bioelectrical Impedance Analysis Overestimates Fat‐Free Mass in Breast Cancer Patients Undergoing Treatment

et al. 2019

View full text Add to dashboard Cite

Background: Bioelectrical impedance analysis (BIA) is commonly used to assess fat-free mass (FFM) and fat mass (FM) in breast cancer patients. However, because of the prevalence of overweight, obesity and variable hydration status in these patients, assumptions for existing prediction equations developed in healthy adults may be violated, resulting in inaccurate body composition assessment. Methods: We measured whole-body FFM using single-frequency BIA (50 kHz) and dual-energy x-ray absorptiometry (DXA) in 48 patients undergoing treatment for breast cancer. We applied raw BIA data to 18 previously published FFM prediction equations (FFM BIA) and compared these estimates to DXA (FFM DXA ; reference method). Results: On average, patients were 52 ± 10 (mean ± SD) years of age and overweight (body mass index: 27.5 ± 5.5 kg/m 2 ; body fat by DXA: 40.1% ± 6.6%). Relative to DXA, BIA overestimated FFM by 4.1 ± 3.4 kg (FFM DXA : 42.0 ± 5.9 kg; FFM BIA : 46.1 ± 3.4 kg). Individual equationgenerated predictions of FFM BIA ranged from 39.6 ± 6.7 to 52.2 ± 5.6 kg, with 16 equations overestimating and 2 equations underestimating FFM BIA compared with FFM DXA. Based on equivalence testing, no equation-generated estimates were equivalent to DXA. Conclusion: Compared with DXA, BIA overestimated FFM in breast cancer patients during treatment. Although several equations performed better than others, none produced values that aligned closely with DXA. Caution should be used when interpreting BIA measurements in this clinical population, and future studies should develop prediction equations specific to breast cancer patients.

show abstract

Section: Introductionmentioning

confidence: 99%